Amarin's (AMRN) Vascepa is taking aim at cardiovascular disease, which is the most destructive disease in the developed world. Not only does a large percentage of the world have heart disease, but it is one the fastest growing populations and the healthcare costs following suit. The world needs novel approaches to address this growing issue, and Vascepa could be an answer. Back in December, the FDA approved Vascepa as the first drug to have the indication for addressing patients with persistent cardiovascular risk beyond statin therapy, which is an extremely broad label that will allow